Cagrilintide news

All news on Cagrilintide (also known as AM833): plants, production capacities, investments and involved companies.

2 February 2026

Novo Nordisk Announces REIMAGINE 2 Trial Results

CagriSema showed superior HbA1c reduction and weight loss over semaglutide in a 68-week trial with type 2 diabetes patients inadequately controlled with metformin.
18 December 2025

Novo Nordisk Seeks FDA Approval for CagriSema, a Weekly Obesity Treatment

CagriSema, combining cagrilintide and semaglutide, shows 23% weight loss in trials. If approved, it offers a new obesity treatment option.
18 December 2025

Novo Nordisk Seeks FDA Approval for CagriSema, a Weekly Obesity Treatment

CagriSema, a weekly injectable combining GLP-1 and amylin analogues, shows promising weight loss results in trials and awaits FDA review for obesity management.
6 November 2025

Novo Nordisk's CagriSema Reduces Blood Pressure and Inflammation, Lowers Heart Disease Risk

CagriSema shows potential in reducing blood pressure, inflammation, and heart disease risk, with ongoing trials to assess cardiovascular outcomes.
5 November 2025

Novo Nordisk Reports 12% Sales Growth in DKK, 15% at CER, and R&D Advances in First Nine Months of 2025

Operating profit rose 5% in DKK, 10% at CER. Obesity care sales up 37%. FDA approved Wegovy® for MASH. Novo Nordisk to acquire Akero Therapeutics. Full-year sales growth forecast at 8-11% CER.
16 September 2025

Novo Nordisk Advances Cagrilintide to Phase 3 Clinical Program After Positive Results

Cagrilintide shows significant weight loss and tolerability in trials, prompting further study in the RENEW phase 3 program for obesity treatment.

Who will be producing Cagrilintide in the future?

Find out with chemXplore Analytics